Format

Send to

Choose Destination
Mol Ther Methods Clin Dev. 2019 May 17;13:503-511. doi: 10.1016/j.omtm.2019.05.003. eCollection 2019 Jun 14.

Endothelin-1 Augments Therapeutic Potency of Human Mesenchymal Stem Cells via CDH2 and VEGF Signaling.

Author information

1
Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
2
Molecular Medicine & Biopharmaceutical Sciences, Seoul National University, Seoul 03080, Republic of Korea.
3
Division of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea.
4
Korean Medical Science Research Center for Healthy-Aging, Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National University, Yangsan, Republic of Korea.
5
UMR-1132 INSERM and University Paris Diderot, Sorbonne Paris Cité, Hôpital Lariboisiére, Paris, France.
6
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Abstract

In our previous study, we identified differences in the levels of CDH2 and vascular endothelial growth factor (VEGF) between effective and ineffective clones of human umbilical cord blood (hUCB) mesenchymal stem cells (MSCs), with regard to the infarcted rat myocardium. In this study, we compared gene expression profiles between the effective and ineffective clones and identified that endothelin-1 (EDN1) is enriched in the effective clone. In the mechanistic analyses, EDN1 significantly increased expression of CDH2 and VEGF through endothelin receptor A (EDNRA), which was prevented by EDNRA blocker, BQ123. To decipher how EDN1 induced gene expression of CDH2, we performed a promoter activity assay and identified GATA2 and MZF1 as inducers of CDH2. EDN1 significantly enhanced the promoter activity of the CDH2 gene, which was obliterated by the deletion or point mutation at GATA2 or MZF1 binding sequence. Next, therapeutic efficacy of EDN1-priming of hUCB-MSCs was tested in a rat myocardial infarction (MI) model. EDN1-primed MSCs were superior to naive MSCs at 8 weeks after MI in improving myocardial contractility (p < 0.05), reducing fibrosis area (p < 0.05), increasing engraftment efficiency (p < 0.05), and improving capillary density (p < 0.05). In conclusion, EDN1 induces CDH2 and VEGF expression in hUCB-MSCs, leading to the improved therapeutic efficacy in rat MI, suggesting that EDN1 is a potential priming agent for MSCs in regenerative medicine.

KEYWORDS:

endothelin-1; human umbilical cord blood mesenchymal stem cell; therapeutic potency

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center